Performance of the CMS electromagnetic calorimeter in Run II and its role in the measurement of the Higgs boson properties

The characterisation of the Higgs boson discovered in 2012 around 125 GeV, and confirmed with the data collected in Run II, requires the precise determination of its mass, width and couplings. The electromagnetic calorimeter (ECAL) of the Compact Muon Solenoid Experiment (CMS) is crucial for measurements in the highest resolution channels, $\mathrm{H}\to\gamma\gamma$ and $\mathrm{H}\to 4$ leptons. In particular the energy resolution, the scale uncertainty and the position resolution for electrons and photons are required to be as good as possible. During Run II the LHC is continuously operating with 25 ns bunch spacing and increasing instantaneous luminosity. The calorimeter reconstruction algorithm has been adapted to cope with increasing levels of pile-up and the calibration and monitoring strategy have been optimized to maintain the excellent performance of the CMS ECAL throughout Run II. We show first performance results from the Run II data taking periods, achieved through energy calibrations using physics events, with a special emphasis on the impact on the measurement of the properties of the Higgs boson and on searches for new physics

Flow diagram showing patient selection at baseline.

<p>Flow diagram showing patient selection at baseline.</p

Additional file 1: of Comparative effectiveness of abatacept versus tocilizumab in rheumatoid arthritis patients with prior TNFi exposure in the US Corrona registry

Table S1 describes the rates of remaining on drug, switching, and discontinuing without starting a new biologic in the TCZ and ABA groups before and after match. Table S2 presents the distribution of prednisone dose increases and decreases between the matched TCA and ABA initiators based on the baseline prednisone usage. Table S3 presents rates of discontinuation and initiation of cDMARDs over the 6-month follow-up. (DOCX 14 kb

The association of patient and disease factors with ISBS^*.

<p>The association of patient and disease factors with ISBS^{<a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0149781#t002fn001" target="_blank">*</a>}.</p

Etanercept and adalimumab patient characteristics at the time of the baseline survey^*.

<p>Etanercept and adalimumab patient characteristics at the time of the baseline survey^{<a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0149781#t001fn001" target="_blank">*</a>}.</p

Additional file 2: Table S2. of Sex differences in gout characteristics: tailoring care for women and men

Dosing of urate-lowering therapies among eligible patients. (DOCX 12 kb

Additional file 3: Figure S1. of Sex differences in gout characteristics: tailoring care for women and men

Comparison of the dietary servings among women and men with gout. The p values represent adjusted analyses adjusting for age, BMI, duration of gout, comorbidity burden [hypertension, diabetes, renal disease, hyperlipidemia], HCTZ use, other diuretic use and current use of a urate-lowering drug. (TIF 320 kb